Literature DB >> 17632782

Mosaic variegated aneuploidy without microcephaly: implications for cytogenetic diagnosis.

Mark A Micale1, David Schran, Sean Emch, Thaddeus W Kurczynski, Nazneen Rahman, Daniel L Van Dyke.   

Abstract

Mosaic variegated aneuploidy (MVA) is a rare condition characterized by multiple trisomies, rarely monosomies, and a non-specific phenotype including microcephaly, growth and mental retardation, mild malformations, and an increased risk of malignancy. We describe a patient with MVA in whom trisomy 19 mosaicism was originally suspected. The patient was the product of an uncomplicated term pregnancy and delivery. Significant findings were mental retardation, obesity, mild epicanthal folds, tapering fingers, relatively small hands and feet, alternating exotropia, nasal speech limited to short phrases, and generalized hypotonia. There is no family history for birth defects, mental retardation, or consanguinity. The initial peripheral blood chromosome study showed trisomy 19 in 4 of 31 metaphase cells. Because mosaic trisomy 19 is rare, the study was extended to 100 cells, wherein two cells with trisomy 8 were identified. A second blood karyotype was obtained and found to be 47,XX,+8[3]/47,XX,+19[3]/47,XX, +18[2]/47,XX,+9[1]/46,XX[91]. Skin fibroblast chromosome studies revealed a 46,XX karyotype in 120 cells examined. There was no evidence of premature centromere separation. Mutations in the BUB1B gene that encodes a key mitotic spindle checkpoint protein have been described in MVA; however, no mutations of this gene were identified in our patient. This case illustrates the importance of considering other possibilities when confronted with an extremely rare diagnosis such as mosaic trisomy 19. In addition, it shows the importance of not simply interpreting a low percentage of multiple aneuploidies as cell culture artifact, because an additional work-up to rule out MVA may be warranted since this diagnosis is associated with an increased risk of malignancy. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17632782     DOI: 10.1002/ajmg.a.31848

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

1.  Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy.

Authors:  Saskia J E Suijkerbuijk; Maria H J van Osch; Frank L Bos; Sandra Hanks; Nazneen Rahman; Geert J P L Kops
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

2.  Pathogenic correlation between mosaic variegated aneuploidy 1 (MVA1) and a novel BUB1B variant: a reappraisal of a severe syndrome.

Authors:  Piero Pavone; Xena Giada Pappalardo; Naira Mustafa; Raffaele Falsaperla; Simona Domenica Marino; Giovanni Corsello; Sebastiano Bianca; Enrico Parano; Martino Ruggieri
Journal:  Neurol Sci       Date:  2022-07-09       Impact factor: 3.307

Review 3.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

4.  Gradual reduction of BUBR1 protein levels results in premature sister-chromatid separation then in aneuploidy.

Authors:  Elodie Bohers; Nasrin Sarafan-Vasseur; Aurélie Drouet; Marianne Paresy; Jean-Baptiste Latouche; Jean-Michel Flaman; Richard Sesboüé; Thierry Frebourg
Journal:  Hum Genet       Date:  2008-10-19       Impact factor: 4.132

Review 5.  The genomically mosaic brain: aneuploidy and more in neural diversity and disease.

Authors:  Diane M Bushman; Jerold Chun
Journal:  Semin Cell Dev Biol       Date:  2013-03-04       Impact factor: 7.727

6.  Mosaic variegated aneuploidy syndrome caused by a CEP57 mutation diagnosed by whole exome sequencing.

Authors:  Diana S Brightman; Sehar Ejaz; Andrew Dauber
Journal:  Clin Case Rep       Date:  2018-06-21

Review 7.  Applications of Genome Editing Technology in Research on Chromosome Aneuploidy Disorders.

Authors:  Silvia Natsuko Akutsu; Kazumasa Fujita; Keita Tomioka; Tatsuo Miyamoto; Shinya Matsuura
Journal:  Cells       Date:  2020-01-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.